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Abstract: An original two-step organocatalytic syn-
thesis of optically active glutarimides from 2-
oxocyclobutane carboxamides is described featuring
an isothiourea-catalyzed two-atom ring-expansive
rearrangement.
Keywords: Nitrogen heterocycles; Organocatalysis;
Rearrangement; Ring expansion; Strained molecules
The glutarimide moiety, that is to say the piperidine-
2,6-dione skeleton, can be found in many natural and
non-natural products having various biological proper-
ties such as antibacterial, antitumoral and anti-inflam-
matory activities, and several marketed drugs contain a
chiral glutarimide unit (Figure 1).[1] While the syn-
thesis of chiral glutarimides in the racemic series is
now enabled at the industrial scale, there have been
only few enantioselective methods reported to synthe-
size glutarimides in non-racemic forms.[2] Actually,
three approaches have been considered so far, relying
either i) on the α-functionalization of preformed
glutarimides,[3] ii) on (3+3) annulation processes from
secondary amides,[4] and more originally iii) on the
two-atom ring contraction of eight-membered benzazo-
cinones (Scheme 1).[5] Herein we propose a comple-
mentary organocatalytic approach that relies on a base-
catalyzed ring rearrangement of 2-oxocyclobutane
carboxamides resulting in a two-atom ring expansion
(Scheme 1).
In early experiments, it was observed that the 2-
oxocyclobutane carboxamide 1a could be catalytically
rearranged into the corresponding glutarimide 2a
ensuing a two-atom ring expansion, using the N-
heterocyclic carbene (NHC) IDipp as the catalyst
(Scheme 2). Anecdotally, the four-membered ring
substrate 1a was conveniently prepared through the
ring-contractive Wolff rearrangement of 2-diazo-cyclo-
pentane-1,3-dione in the presence of 4-nitroaniline,[6]
and the synthesis of glutarimide 2a is thus based on a
Figure 1. Selected structurally simple natural (left) and non-
natural (right) biologically active glutarimides.
Scheme 1. Enantioselective synthetic approaches to glutari-
mides.
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one-atom ring contraction/two-atom ring expansion
sequence. From there, it was anticipated that a similar
ring rearrangement would occur with the more com-
plex and highly enantioenriched 2-oxocyclobutane
carboxamide 3a derived from the enantioselective
organocatalytic Michael addition of cyclobutanone 1a
to nitrostyrene catalyzed by the bifunctional amino-
catalyst OC, as described in a previous article.[7] Some
representative basic catalysts were screened for the
conversion of enantiopure 3a (er >200:1) into the
corresponding glutarimide 4a (Scheme 3). The NHCs
IDipp and TPhPh afforded encouraging yields of the
expected glutarimide product 4a as mixtures of the
two possible diastereomers, albeit as nearly racemic
materials, indicating a rapid racemization under these
conditions. Similar observations resulted from the trials
with tri-tert-butylphosphine (TBP) and triethylamine
(TEA). Interestingly, DMAP and its analog 4PP
afforded both diastereomers of 4a with this time
relatively good retentions of optical purity. In contrast,
catalytic triphenylphosphine (TPP) or DBU did not
allow the isolation of 4a. Finally, it was found that
20 mol% of DHPB[8] is optimum to promote this ring
rearrangement efficiently, allowing the isolation of 4a
(dr=2:1) without significant loss of optical purity,
indicating negligible racemization processes in that
case. It was briefly explored if the two-step sequence
could be performed in one-pot conditions, without
isolating the intermediate Michael adduct 3a. When
20 mol% DHPB were added to the product reaction
mixture of the first step, the glutarimide 4a (dr=2.4:1)
was produced efficiently (quant. by 1H NMR analysis)
after 8 hours at 28 °C but with important racemization
(er=3.3:1 and 8.7:1), showing catalysts incompatibil-
ity and a preferred stepwise synthetic sequence.
The stereochemical outcome of the ring rearrange-
ment reaction 3a!4a was questioned. The issue of
racemization was attributed to catalytic retro-Michael/
Michael processes of 3a involving the Brønsted base
properties of the various achiral catalysts depicted in
Scheme 3. This could be confirmed experimentally by
a series of cross-experiments in the case of catalyst
IDipp (Scheme 4).
Indeed, when the racemic glutarimide 4a was
allowed to react with the nitroolefin having an extra 4-
methyl group on the benzene ring in the presence of
IDipp or DHPB, no reaction occurred and 4a was
recovered quantitatively. This indicates that no retro-
Michael/Michael process is occurring on the glutari-
mide product 4a under these conditions. In contrast,
when the racemic 2-oxocyclobutane carboxamide 3a
Scheme 2. Early observation of the base-catalyzed ring rear-
rangement of the 2-oxocyclobutane carboxamide 1a into the
glutarimide 2a.
Scheme 3. Screening of basic catalysts for the ring rearrange-
ment of 2-oxocyclobutane carboxamide 3a. The major diaster-
eomer of glutarimide 4a is depicted.
Scheme 4. Cross-experiments probing retro-Michael/Michael
racemization processes of 3a with IDipp and not with DHPB.
The major diastereomers are depicted.
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was employed as the substrate with the IDipp catalyst
under similar conditions, the glutarimide 4a (43%)
could be obtained together with the cross-product
glutarimide incorporating the nitroolefin having an
extra 4-methyl group (12%). These experiments dem-
onstrate that IDipp-catalyzed retro-Michael/Michael
processes occurred prior to the ring rearrangement of
3a.[9] Similar cross-experiments were performed with
DHPB instead of IDipp and, as expected, no cross-
product could be detected in these cases showing that
DHPB do not catalyze retro-Michael/Michael proc-
esses from 3a at a significant rate. The low diaster-
eoselectivity of the transformation 3a!4a is seem-
ingly governed by thermodynamics due to relatively
rapid DHPB-catalyzed epimerization at the imide
enolizable position in product 4a as recently observed
in closely related cases.[5b,10] Supportive to this hypoth-
esis, the relative Gibbs free energies of (S,R)-4a and
its diastereomer (R,R)-epi-4a were calculated using
several density functional theory (DFT) methods,
indicating that 4a is the thermodynamic diastereomer,
though by only 2.2–3.6 kJ.mol 1 corresponding to a
2.4–4.3:1 ratio at equilibrium (see Supporting Informa-
tion).
The scope and functional group tolerance of the
glutarimides accessible by this approach were ex-
plored, first focusing on the electronics of the
secondary amide group in cyclobutanones 3
(Scheme 5). It turned out that the two-atom ring-
expansive rearrangement is only operative with elec-
tron-withdrawing N-aryl amide R1 substituents, afford-
ing the glutarimides 4a–e in good yields and high
enantioselectivities. In contrast, cyclobutanones 3f–h
having electron-donating amide substituents were
unreactive toward DHPB. Then, some representative
nitroolefins were screened, which afforded the gluta-
rimides 4 i–o having various aryl, heteroaryl or alkyl
R2 substituents. The observed slight erosions of er in
products 4b–e and 4 i–o were attributed to DHPB-
catalyzed retro-Michael/Michael processes from the 2-
oxocyclobutane carboxamides 3b–e and 3 i–o, respec-
tively, as demonstrated above for 3a with IDipp (see
Scheme 4). Overall, an original enantioselective two-
step approach to synthesize optically active glutari-
mides from 2-oxocyclobutane carboxamides has been
discovered based on a two-step Michael/ring rear-
rangement sequence resulting in a two-atom ring
expansion. Using this method, the glutarimide products
described herein were generally obtained in good
yields and high enantioselectivities, albeit generally as
ca. 2:1 mixtures of the two possible diastereomers.
Mechanistically, two distinct scenarios are plausible
to account for the observed ring rearrangement 3!4:
i) the basic catalyst is acting as a Brønsted base BB
generating the corresponding amide isothiouronium
salt of 3 to trigger an anionic ring closing/ring
expansion sequence leading to 4 (Scheme 6, left), or ii)
the basic catalyst is acting as a nucleophilic Lewis
base LB promoting a ring opening/ring closing
sequence to give 4 (Scheme 6, right). With the
intention to gain insight in the intimate mechanism of
this original transformation with DHPB as the catalyst,
we investigated these two scenarios by computational
modelization using DFT methods at an appropriate
level of theory (see Supporting Information for de-
tails). The model transformations I!V (R=NO2 and
OMe) were selected for this part of the study, and the
mechanism involving DHPB as a Brønsted base was
first considered (Scheme 7). As it could be anticipated,
Scheme 5. Scope of the reaction. The major diastereomers are
depicted. nd=not determined.
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the ring rearrangement of the anion II directly derived
from I into the anion IV precursor of V was found a
two-step process proceeding via the bicyclic intermedi-
ate III. The reaction barrier of the overall rearrange-
ment was calculated at +113.7 kJ.mol 1 from the
substrate I with R=NO2 (see Supporting Information
for details). The alternative mechanism involving
DHPB as a catalytic nucleophilic Lewis base was then
examined (Scheme 8). In this case it was found that
the reaction is initiated by the formation of the
ephemeral tetrahedral intermediate VI resulting from
the addition of DHPB to the ketone carbonyl group
with relatively low barriers. The fragmentation of VI
into the acyl isothiouronium intermediate VII was
computed as the rate limiting step in both the R=NO2
and R=OMe series, with reaction barriers at +86.7
and +111.5 kJ.mol 1, respectively. Then, a thermody-
namically favored tautomery can afford intermediate
VIII with this time the negative charge located on the
nitrogen atom of the amide group. The relatively
important stabilization energies in the zwitterionic
intermediates VIII (R=NO2 and OMe) was attributed,
at least in part, to strong π donor-acceptor stabilizing
interactions between the negatively charged N-aryl
amide planar moiety and the positively charged acyl
isothiouronium planar moiety, with interplanar distan-
ces of ca. 3.2 Å for R=NO2 and 3.4 Å for R=OMe
(Figure 2). Finally, intermediate VIII can cyclize in an
irreversible manner to afford the glutarimide product V
and regenerate the catalyst. Overall, these calculations
with DHPB as the catalyst indicate i) that both
Scheme 6. Plausible mechanistic scenarios with the catalyst
acting as a Brønsted base BB (left) or a nucleophilic Lewis base
LB (right).
Scheme 7. Calculated energy profile for the model transforma-
tion I!V (R=NO2) with DHPB employed as a catalytic
Brønsted base [DFT, M06-2X-D/6-311+ +G(d,p) including a
solvation model for dichloromethane]. Energies are Gibbs free
energies expressed in kJ.mol 1.
Scheme 8. Calculated energy profile for the model transforma-
tion I!V (R=NO2 and R=OMe) with DHPB employed as a
catalytic Lewis base [DFT, M06-2X-D/6-311+ +G(d,p) includ-
ing a solvation model for dichloromethane]. Energies are Gibbs
free energies expressed in kJ.mol 1, and significant interactions
are highlighted in brown color with inter atomic distances
provided for the R=NO2 series.
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mechanisms are energetically possible, ii) that the
mechanism involving the catalyst as a nucleophilic
Lewis base is kinetically favored, and iii) that the
reaction with R=OMe would proceed at an extremely
slow rate under the reaction conditions, which is in
perfect agreement with the experimental results (see
compound 4g not obtained in Scheme 5). In order to
confirm this substituent effect, the analog of 1a having
a OMe substituent in place of the NO2 group was
allowed to react with DHPB (20 mol%) in dichloro-
methane without promoting a detectable reaction after
14 h. Overall, it seems that the ring rearrangement of
2-oxocyclobutane carboxamides into glutarimides cata-
lyzed by DHPB described herein proceeded via acyl
isothiouronium intermediates of type VII/VIII.[11] Of
course, these conclusions are only valid for DHPB,
and it cannot be excluded that the other operative
catalysts depicted in Scheme 3 behave otherwise.[12]
In summary, an original approach was discovered
for the synthesis of optically active glutarimides. It is
based on a two-step organocatalytic approach involv-
ing an enantioselective Michael addition of 2-oxocy-
clobutane carboxamides to nitroolefins using a chiral
bifunctional aminocatalyst, followed by a two-atom
ring-expansive rearrangement catalyzed by an achiral
isothiourea catalyst. The glutarimide products prepared
by this approach were generally obtained as mixtures
of the two possible diastereomers in good yields and
high enantioselectivities. Stereochemical outcomes
were rationalized, and a computational mechanistic
study showed that the ring rearrangement step is
seemingly promoted by the nucleophilicity and Lewis
basicity of the isothiourea catalyst.
Experimental Section
General Information
See the Supporting Information.
Synthesis of 2-oxocyclobutane Carboxamides 3
The syntheses and characterization data of optically active 3a,
3e–h, and 3j–o were reported in a previous article.[7] Optically
active 3b–d and 3 i were prepared following the same
procedure and their characterization data are provided below.
All racemic 2-oxocyclobutane carboxamides 3a–o were pre-
pared from the corresponding unsubstituted 2-oxocyclobutane
carboxamides 1[6a] and the corresponding nitroolefins using the
polystyrene-supported phosphazene catalyst known as P-
BEMP.[13]
Compound 3b: Following the general procedure,[7] the reaction
between the 2-oxocyclobutane carboxamide 1 (R1=4-
CO2Et C6H4, 100 mg, 0.36 mmol) and nitrostyrene (45 mg,
0.30 mmol) in anhydrous dichloromethane (2 mL) with catalyst
OC (9 mg, 0.015 mmol) for 14 h afforded the 2-oxocyclobutane
carboxamide 3b (94 mg, 76% yield, dr=26:1, er=49:1) as a
white solid. Rf=0.40 (petrol ether/ethyl acetate, 2:1). Mp=
182–184 °C (amorphous). [α]D25= 153.3 (c=1.0, CHCl3).
HRMS (ESI+) m/z calcd for C22H23N2O6+ [M+H]+ =
411.1551, found=411.1551. 1H NMR (400 MHz, CDCl3)
major diastereomer: δ 8.26 (br s, 1H), 8.02 (d, J=8.4 Hz, 2H),
7.57 (d, J=8.8 Hz, 2H), 7.40–7.31 (m, 3H), 7.30–7.26 (m, 2H),
4.97 (dd, J=14.0, 10.6 Hz, 1H), 4.86 (dd, J=14.0, 5.0 Hz,
1H), 4.36 (q, J=7.1 Hz, 2H), 4.23 (dd, J=10.6, 5.0 Hz, 1H),
2.82 (ddd, J=15.1, 10.2, 4.1 Hz, 1H), 2.63–2.45 (m, 1H), 2.40–
2.17 (m, 2H), 1.38 (t, J=7.1 Hz, 3H). 13C{1H} NMR
(100 MHz, CDCl3) major diastereomer: δ 208.7 (C), 166.0 (C),
165.7 (C), 140.9 (C), 133.4 (C), 130.9 (2CH), 129.4 (2CH),
129.1 (CH), 128.5 (2CH), 127.0 (C), 119.4 (2CH), 76.2 (C),
74.7 (CH2), 61.1 (CH2), 47.0 (CH), 44.5 (CH2), 17.9 (CH2),
14.4 (CH3). HPLC: Chiralpak IE eluted with 1:1 heptane/
ethanol at 1 mL/min at 25 °C, UV detection at 270 nm, retention
times: major enantiomer 7.88 min, minor enantiomer 10.00 min.
Compound 3c: Following the general procedure,[7] the reaction
between the 2-oxocyclobutane carboxamide 1 (R1=4-
CN C6H4, 77 mg, 0.36 mmol) and nitrostyrene (45 mg,
0.30 mmol) in anhydrous dichloromethane (2 mL) with catalyst
OC (9 mg, 0.015 mmol) for 14 h afforded the 2-oxocyclobutane
carboxamide 3c (72 mg, 66% yield, dr=20:1, er=56:1) as a
white solid. Rf=0.51 (petrol ether/ethyl acetate, 2:1). Mp=
136-138 °C (amorphous). [α]D25= 127.4 (c=1.0, CHCl3).
HRMS (ESI+) m/z calcd for C20H18N3O4+ [M+H]+ =
364.1292, found=364.1290. 1H NMR (400 MHz, CDCl3)
major diastereomer: δ 8.32 (br s, 1H), 7.61 (br s, 4H), 7.40–
7.32 (m, 3H), 7.29–7.26 (m, 2H), 4.96 (dd, J=14.0, 10.2 Hz,
1H), 4.85 (dd, J=14.0, 5.2 Hz, 1H), 4.24 (dd, J=10.2, 5.2 Hz,
1H), 2.82 (ddd, J=15.1, 10.2, 4.5 Hz, 1H), 2.63–2.44 (m, 1H),
2.43–2.18 (m, 2H). 13C{1H} NMR (100 MHz, CDCl3) major
diastereomer: δ 208.5 (C), 165.9 (C), 140.8 (C), 133.3 (2CH),
133.3 (C), 129.4 (2CH), 129.1 (C), 128.4 (2CH), 120.1 (2CH),
118.6 (CH), 108.1 (C), 77.1 (C), 74.6 (CH2), 46.8 (CH), 44.5
(CH2), 17.8 (CH2). HPLC: Chiralpak IA eluted with 1:1
heptane/ethanol at 1 mL/min at 25 °C, UV detection at 240 nm,
retention times: major enantiomer 6.07 min, minor enantiomer
9.23 min.
Compound 3d: Following the general procedure,[7] the reaction
between the 2-oxocyclobutane carboxamide 1 (R1=4-
CF3 C6H4, 93 mg, 0.36 mmol) and nitrostyrene (45 mg,
0.30 mmol) in anhydrous dichloromethane (2 mL) with catalyst
Figure 2. Top and side views of optimized geometries for
intermediates VIII with R=NO2 (left) and R=OMe (right).
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OC (9 mg, 0.015 mmol) for 14 h afforded the 2-oxocyclobutane
carboxamide 3d (100 mg, 82% yield, dr=22:1, er=55:1) as a
white solid. Rf=0.60 (petrol ether/ethyl acetate, 2:1). Mp=
131-133 °C (amorphous). [α]D25= 124.6 (c=1.0, CHCl3).
HRMS (ESI+) m/z calcd for C20H18F3N2O4+ [M+H]+ =
407.1213, found=407.1213. 1H NMR (400 MHz, CDCl3)
major diastereomer: δ 8.25 (br s, 1H), 7.56–7.64 (m, 4H), 7.42–
7.32 (m, 3H), 7.28 (dd, J=7.7, 1.7 Hz, 2H), 4.97 (dd, J=14.0,
10.4 Hz, 1H), 4.87 (dd, J=14.0, 5.1 Hz, 1H), 4.24 (dd, J=
10.3, 5.1 Hz, 1H), 2.82 (ddd, J=15.1, 10.2, 4.1 Hz, 1H), 2.60–
2.46 (m, 1H), 2.41–2.19 (m, 2H). 13C{1H} NMR (100 MHz,
CDCl3) major diastereomer: δ 208.7 (C), 165.9 (C), 139.9 (C),
133.4 (C), 129.4 (2CH), 129.1 (CH), 128.5 (2CH), 126.9 (q,
JC F=28 Hz, C), 126.4 (q, JC–F=4 Hz, 2CH), 123.9 (q, JC–F=
270 Hz, C), 120.0 (2CH), 76.1 (C), 74.7 (CH2), 47.0 (CH), 44.5
(CH2), 17.9 (CH2). 19F{13C} NMR (282 MHz, CDCl3): δ  62.3.
HPLC: Chiralpak IA eluted with 7:3 heptane/ethanol at 1 mL/
min at 25 °C, UV detection at 254 nm, retention times: major
enantiomer 6.33 min, minor enantiomer 12.95 min.
Compound 3 i: Following the general procedure,[7] the reaction
between the 2-oxocyclobutane carboxamide 1 (R1=4-
NO2 C6H4, 76 mg, 0.33 mmol) and (E)-1-methyl-4-(2-nitro-
vinyl)benzene (45 mg, 0.27 mmol) in anhydrous dichlorome-
thane (2 mL) with catalyst OC (8 mg, 0.013 mmol) for 16 h
afforded the 2-oxocyclobutane carboxamide 3 i (70 mg, 65%
yield, dr >20:1, er=66:1) as a white solid. Rf=0.50 (petrol
ether/ethyl acetate, 2:1). Mp=81-83 °C (amorphous). [α]D25=
 85.5 (c=0.5, CHCl3). HRMS (ESI+) m/z calcd for
C20H20N3O6+ [M+H]+ =398.1347, found=398.1345. 1H
NMR (400 MHz, CDCl3) major diastereomer: δ 8.43 (br s, 1H),
8.24 (d, J=9.0 Hz, 2H), 7.69 (d, J=9.0 Hz, 2H), 7.23–7.11 (m,
4H), 4.94 (dd, J=13.9, 10.1 Hz, 1H), 4.84 (dd, J=13.9,
5.3 Hz, 1H), 4.21 (dd, J=10.1, 5.3 Hz, 1H), 2.84 (ddd, J=
18.2, 10.1, 4.3 Hz, 1H), 2.61–2.51 (m, 1H), 2.43–2.23 (m, 2H),
2.33 (s, 3H). 13C{1H} NMR (100 MHz, CDCl3) major diaster-
eomer: δ 208.9 (C), 166.3 (C), 144.3 (C), 142.6 (C), 139.3 (C),
130.2 (2 CH), 130.1 (C), 128.4 (2CH), 125.3 (2CH), 119.8
(2CH), 76.3 (C), 74.8 (CH2), 46.7 (CH), 44.7 (CH2), 21.2
(CH3), 17.8 (CH2). HPLC: Chiralpak IG eluted with 7:3
heptane/ethanol at 1 mL/min at 25 °C, UV detection at 254 nm,
retention times: major enantiomer 11.23 min, minor enantiomer
20.37 min.
General Procedure for the Ring Rearrangement
To a solution of 2-oxocyclobutane carboxamide 3 (ca.
0.2 mmol) in anhydrous dichloromethane (ca. 2 mL) was added
the catalyst DHPB (20 mol%). The reaction was stirred at 28 °C
for the time indicated below with periodical monitoring by TLC
analysis, concentrated under vacuum and directly purified by
flash chromatography to give the glutarimide product 4.
Compound 4a: Following the general procedure, 3a (43 mg,
0.11 mmol, dr=20:1, er >200:1) reacted with DPHB (4 mg,
0.021 mmol) for 8 h to provide 4a (39 mg, 91%, dr=2:1, er=
199:1 and 111:1) as a white solid. Rf=0.30 (petrol ether/ethyl
acetate, 3:1). HRMS (ESI+) m/z calcd for C19H18N3O6+ [M+
H]+ =384.1190, found=384.1190. 1H NMR (400 MHz,
CDCl3) major diastereomer: δ 8.32 (d, J=9.0 Hz, 2H), 7.44–
7.33 (m, 3H), 7.29–7.21 (m, 3H), 7.17 (d, J=8.9 Hz, 1H), 5.22
(dd, J=13.4, 7.6 Hz, 1H), 5.02 (dd, J=13.3, 7.6 Hz, 1H), 4.06
(ddd, J=7.6, 7.6, 3.5 Hz, 1H), 3.18 (ddd, J=12.0, 5.1, 3.6 Hz,
1H), 2.84 (ddd, J=17.4, 4.2, 4.2 Hz, 1H), 2.79–2.63 (m, 1H),
2.22–2.10 (m, 1H), 2.03 (dd, J=12.4, 4.7 Hz, 1H); minor
diastereomer: δ 8.32 (d, J=9.0 Hz, 2H), 7.44–7.33 (m, 3H),
7.29–7.21 (m, 3H), 7.17 (d, J=8.9 Hz, 1H), 5.14 (dd, J=13.5,
7.4 Hz, 1H), 4.77 (dd, J=13.5, 7.3 Hz, 1H), 4.17 (ddd, J=7.5,
7.5, 7.5 Hz, 1H), 3.07 (ddd, J=8.9, 8.9, 4.9 Hz, 1H), 2.92 (ddd,
J=17.9, 6.8, 4.8 Hz, 1H), 2.79–2.63 (m, 1H), 1.97 (dd, J=
12.7, 4.6 Hz, 1H), 1.71–1.83 (m, 1H). 13C{1H} NMR
(100 MHz, d8-tetrahydrofuran) major diastereomer: δ 172.6
(C), 170.7 (C), 147.5 (C), 142.0 (C), 137.7 (C), 130.1 (2CH),
128.7 (2CH), 128.6 (2CH), 127.7 (CH), 123.6 (2CH), 76.4
(CH2), 45.9 (CH), 44.7 (CH), 32.2 (CH2), 20.6 (CH2); minor
diastereomer: δ 172.7 (C), 170.7 (C), 147.5 (C), 142.0 (C),
137.5 (C), 130.1 (2CH), 128.6 (2CH), 127.7 (CH), 123.6
(2CH), 77.6 (CH2), 44.7 (CH), 43.1 (CH), 31.0 (CH2), 20.1
(CH2). HPLC: Chiralpak IC eluted with 1:1 heptane/ethanol at
1 mL/min at 25 °C, UV detection at 205 and 230 nm, retention
times: major diastereomer 8.10 min (major enantiomer) and
6.38 min (minor enantiomer), minor diastereomer 6.98 min
(major enantiomer) and 9.13 min (minor enantiomer).
Compound 4b: Following the general procedure, 3b (65 mg,
0.16 mmol, dr=26:1, er=49:1) reacted with DPHB (6 mg,
0.032 mmol) for 48 h to provide 4b (43 mg, 66%, dr=1.4:1,
er=39:1 and 21:1) as a white solid. Rf=0.35 (petrol ether/ethyl
acetate, 3:1). HRMS (ESI+) m/z calcd for C22H23N2O6+ [M+
H]+ =411.1551, found=411.1552. 1H NMR (400 MHz,
CDCl3) major diastereomer: δ 8.14 (d, J=8.9 Hz, 2H), 7.44–
7.20 (m, 5H), 7.05 (d, J=8.9 Hz, 2H), 5.20 (dd, J=13.5,
7.1 Hz, 1H), 5.05 (dd, J=13.5, 8.1 Hz, 1H), 4.39 (q, J=7.1 Hz,
2H), 4.02 (ddd, J=7.6, 7.6, 3.6 Hz, 1H), 3.16 (ddd, J=12.0,
5.1, 3.7 Hz, 1H), 2.78 (ddd, J=12.5, 8.4, 4.3 Hz, 1H), 2.74–
2.59 (m, 1H), 2.15–1.67 (m, 2H), 1.39 (t, J=7.1 Hz, 3H);
minor diastereomer: δ 8.14 (d, J=8.9 Hz, 2H), 7.44–7.20 (m,
5H), 7.12 (d, J=8.9 Hz, 2H), 5.16 (dd, J=13.3, 6.9 Hz, 1H),
4.78 (dd, J=13.3, 8.0 Hz, 1H), 4.39 (q, J=7.1 Hz, 2H), 4.16
(dd, J=15.3, 8.0 Hz, 1H), 3.03 (ddd, J=9.3, 9.3, 4.9 Hz, 1H),
2.88 (ddd, J=17.9, 6.5, 4.8 Hz, 1H), 2.74–2.59 (m, 1H), 2.15–
1.67 (m, 2H), 1.39 (t, J=7.1 Hz, 3H). 13C{1H} NMR
(100 MHz, CDCl3) major diastereomer: δ 172.8 (C), 171.2 (C),
165.7 (C), 139.0 (C), 136.0 (C), 130.9 (C), 130.6 (2CH), 129.2
(2CH), 128.8 (2CH), 128.7 (CH), 128.5 (2CH), 78.1 (CH2),
61.2 (CH2), 45.4 (CH), 44.8 (CH2), 32.3 (CH2), 21.5, (CH2)
14.3 (CH3); minor diastereomer: δ 172.9 (C), 171.2 (C), 165.7
(C), 139.0 (C), 136.3 (C), 130.9 (C), 129.4 (2CH), 128.6 (2CH),
128.7 (CH), 128.6 (2CH), 128.2 (2CH), 77.2 (CH2), 61.2 (CH2),
44.8 (CH), 43.7 (CH2), 31.2 (CH2), 20.5 (CH2), 14.3 (CH3).
HPLC: Chiralpak IA eluted with 1:1 heptane/ethanol at 1 mL/
min at 25 °C, UV detection at 220 nm, retention times: major
diastereomer 22.26 min (major enantiomer) and 35.51 min
(minor enantiomer), minor diastereomer 41.26 min (major
enantiomer) and 32.57 min (minor enantiomer).
Compound 4c: Following the general procedure, 3c (50 mg,
0.14 mmol, dr=20:1, er=56:1) reacted with DPHB (5 mg,
0.026 mmol) for 72 h to provide 4c (24 mg, 48%, dr=1.6:1,
er=40:1 and 13:1) as a white solid. Rf=0.28 (petrol ether/ethyl
acetate, 3:1). HRMS (ESI+) m/z calcd for C20H21N4O4+ [M+
NH4]+ =381.1557, found=381.1556. 1H NMR (400 MHz,
CDCl3) major diastereomer: δ 7.74 (d, J=8.7 Hz, 2H), 7.42–
7.32 (m, 3H), 7.26–7.20 (m, 2H), 7.11 (d, J=8.7 Hz, 2H), 5.20
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(dd, J=13.4, 7.5 Hz, 1H), 5.02 (dd, J=13.3, 7.7 Hz, 1H), 4.05
(ddd, J=7.6, 3.6, 3.6 Hz, 1H), 3.16 (ddd, J=12.0, 5.1, 3.6 Hz,
1H), 2.81 (ddd, J=17.4, 4.3, 4.3 Hz, 1H), 2.77–2.64 (m, 1H),
2.19–2.09 (m, 1H), 2.06–1.92 (m, 1H); minor diastereomer:
δ 7.75 (d, J=8.7 Hz, 2H), 7.44–7.32 (m, 3H), 7.24–7.20 (m,
2H), 7.18 (d, J=8.7 Hz, 2H), 5.14 (dd, J=13.5, 7.3 Hz, 1H),
4.76 (dd, J=13.5, 7.4 Hz, 1H), 4.16 (ddd, J=7.5, 7.5, 7.5 Hz,
1H), 3.05 (ddd, J=8.9, 8.9, 4.9 Hz, 1H), 2.90 (ddd, J=17.9,
6.8, 4.8 Hz, 1H), 2.77–2.64 (m, 1H), 2.06–1.92 (m, 1H), 1.79–
1.70 (m, 1H). 13C{1H} NMR (100 MHz, CDCl3) major
diastereomer: δ 172.7 (C), 171.1 (C), 139.2 (C), 136.1 (C),
133.2 (2CH), 129.8 (2CH), 129.4 (2CH), 128.9 (CH), 128.8
(2CH), 118.1 (C), 113.0 (C), 77.3 (CH2), 45.8 (CH), 45.5 (CH),
32.4 (CH2), 21.5 (CH2); minor diastereomer: δ 172.9 (C), 171.2
(C), 139.2 (C), 136.3 (C), 133.2 (2CH), 129.8 (2CH), 129.6
(2CH), 128.8 (CH), 128.3 (2CH), 118.2 (C), 113.0 (C), 78.0
(CH2), 45.0 (CH), 43.6 (CH), 31.1 (CH2), 20.5 (CH2). HPLC:
Chiralpak IC eluted with 7:3 heptane/ethanol at 1 mL/min at
25 °C, UV detection at 220 nm, retention times: major diaster-
eomer 17.05 min (major enantiomer) and 11.83 min (minor
enantiomer), minor diastereomer 13.49 min (major enantiomer)
and 19.19 min (minor enantiomer).
Compound 4d: Following the general procedure, 3d (72 mg,
0.18 mmol, dr=22:1, er=55:1) reacted with DPHB (7 mg,
0.037 mmol) for 72 h to provide 4d (54 mg, 75%, dr=1.6:1,
er=43:1 and 21:1) as a white solid. Rf=0.45 (petrol ether/ethyl
acetate, 3:1). HRMS (ESI+) m/z calcd for C20H18F3N2O4+ [M
+H]+ =407.1213, found=407.1213. 1H NMR (400 MHz,
CDCl3) major diastereomer: δ 7.75 (d, J=8.7 Hz, 2H), 7.43–
7.38 (m, 3H), 7.24–7.33 (m, 2H), 7.14 (d, J=8.7 Hz, 2H), 5.23
(dd, J=13.4, 7.3 Hz, 1H), 5.07 (dd, J=13.4, 7.9 Hz, 1H), 4.05
(ddd, J=7.6, 7.6, 3.6 Hz, 1H), 3.19 (ddd, J=12.0, 5.1, 3.6 Hz,
1H), 2.83 (ddd, J=17.4, 4.3, 4.3 Hz, 1H), 2.76–2.62 (m, 1H),
2.14 (ddd, J=17.5, 9.1, 5.2 Hz, 1H), 2.06–1.93 (m, 1H); minor
diastereomer: δ 7.75 (d, J=8.7 Hz, 2H), 7.43–7.38 (m, 3H),
7.24–7.33 (m, 2H), 7.21 (d, J=8.7 Hz, 2H), 5.17 (dd, J=13.4,
7.1 Hz, 1H), 4.79 (dd, J=13.4, 7.7 Hz, 1H), 4.19 (dd, J=15.4,
7.6 Hz, 1H), 3.08 (ddd, J=9.2, 9.2, 4.9 Hz, 1H), 2.93 (ddd, J=
17.9, 6.7, 4.8 Hz, 1H), 2.76–2.66 (m, 1H), 2.06–1.93 (m, 1H),
1.77 (ddd, J=14.2, 9.6, 4.7 Hz, 1H). 13C{1H} NMR (100 MHz,
CDCl3) major diastereomer: δ 172.9 (C), 171.2 (C), 138.3 (C),
136.1 (C), 131.1 (q, JC–F=32.6 Hz, C), 129.4 (2CH), 129.1
(2CH), 128.9 (2CH), 128.8 (CH), 126.6 (q, JC–F=3.7 Hz, 2CH),
123.8 (q, JC–F=270 Hz, CF3), 77.4 (CH2), 45.9 (CH), 45.5
(CH), 32.4 (CH2), 21.6 (CH2); minor diastereomer: δ 173.0 (C),
171.3 (C), 138.2 (C), 136.4 (C), 131.1 (q, JC–F=32.6 Hz, C),
129.5 (2CH), 129.2 (2CH), 128.7 (CH), 128.3 (2CH), 126.5 (q,
JC–F=3.7 Hz, 2CH), 123.7 (q, JC–F=270 Hz, CF3), 78.1 (CH2),
45.0 (CH), 43.7 (CH), 31.2 (CH2), 20.6 (CH2). 19F{13C} NMR
(282 MHz, CDCl3) major diastereomer: δ  62.7; minor diaster-
eomer: δ  62.7. HPLC: Chiralpak IC eluted with 8:2 heptane/
ethanol at 1 mL/min at 25 °C, UV detection at 235 nm, retention
times: major diastereomer 11.67 min (major enantiomer) and
8.25 min (minor enantiomer), minor diastereomer 9.46 min
(major enantiomer) and 15.33 min (minor enantiomer).
Compound 4e: Following the general procedure, 3e (91 mg,
0.19 mmol, dr=25:1, er=58:1) reacted with DPHB (7 mg,
0.037 mmol) for 24 h to provide 4e (77 mg, 85%, dr=1.5:1,
er=44:1 and 38:1) as a colorless oil. Rf=0.60 (petrol ether/
ethyl acetate, 3:1). HRMS (ESI+) m/z calcd for C21H20
F6N3O4+ [M+NH4]+ =492.1353, found=492.1350. 1H NMR
(400 MHz, CDCl3) major diastereomer: δ 7.92 (s, 1H), 7.53–
7.35 (m, 5H), 7.26–7.19 (m, 2H), 5.21 (dd, J=13.4, 7.5 Hz,
1H), 5.03 (dd, J=13.4, 7.8 Hz, 1H), 4.03 (ddd, J=7.6, 7.6,
3.5 Hz, 1H), 3.18 (ddd, J=11.9, 5.2, 3.5 Hz, 1H), 2.82 (dd, J=
17.4, 4.2, 4.2 Hz, 1H), 2.77–2.61 (m, 1H), 2.23–2.12 (m, 1H),
2.07–1.90 (m, 1H); minor diastereomer: δ 7.92 (s, 1H), 7.53–
7.35 (m, 5H), 7.26–7.19 (m, 2H), 5.14 (dd, J=13.4, 7.3 Hz,
1H), 4.78 (dd, J=13.4, 7.6 Hz, 1H), 4.19 (ddd, J=7.6, 7.6,
7.6 Hz, 1H), 3.06 (ddd, J=9.7, 8.1, 4.9 Hz, 1H), 2.91 (ddd, J=
17.9, 6.2, 4.7 Hz, 1H), 2.77–2.61 (m, 1H), 2.07–1.90 (m, 1H),
1.77 (dddd, J=14.4, 10.1, 10.1 4.6 Hz, 1H). 13C{1H} NMR
(100 MHz, CDCl3) major diastereomer: δ 172.8 (C), 171.0 (C),
136.5 (C), 135.8 (C), 132.8 (q, JC–F=34.3 Hz, 2CF3), 129.5
(2CH), 129.3 (2CH), 128.9 (CH), 128.8 (2CH), 122.8 (q, JC–F=
273.7 Hz, 2CF3), 122.8 (q, JC–F=3.7 Hz, CH), 77.2 (CH2), 45.9
(CH), 45.5 (CH), 32.2 (CH2), 21.4 (CH2); minor diastereomer:
δ 172.9 (C), 171.1 (C), 136.5 (C), 136.1 (C), 132.8 (q, JC–F=
34.3 Hz, 2CF3), 129.4 (2CH), 129.3 (2CH), 128.7 (2CH), 128.7
(CH), 132.7 (q, JC–F=272.7 Hz, 2CF3), 122.8 (q, JC–F=3.7 Hz,
CH), 78.0 (CH2), 44.9 (CH), 43.7 (CH), 31.3 (CH2), 20.4 (CH2).
19F{13C} NMR (282 MHz, CDCl3) major diastereomer: δ
 62.8; minor diastereomer: δ  62.9. HPLC: Chiralpak IF
eluted with 9:1 heptane/ethanol at 1 mL/min at 25 °C, UV
detection at 210 nm, retention times: major diastereomer
13.26 min (major enantiomer) and 6.20 min (minor enantiom-
er), minor diastereomer 7.38 min (major enantiomer) and
8.19 min (minor enantiomer).
Compound 4 i: Following the general procedure, 3 i (65 mg,
0.16 mmol, dr=26:1, er=49:1) reacted with DPHB (6 mg,
0.032 mmol) for 48 h to provide 4 i (43 mg, 66%, dr=1.7:1,
er=12:1 and 19:1) as a white solid. Rf=0.30 (petrol ether/ethyl
acetate, 2:1). HRMS (ESI+) m/z calcd for C20H20 N3O6+ [M+
H]+ =398.1347, found=398.1345. 1H NMR (400 MHz,
CDCl3) major diastereomer: δ 8.32 (d, J=8.7 Hz, 2H), 7.25–
7.09 (m, 6H), 5.20 (dd, J=13.3, 7.6 Hz, 1H), 4.99 (dd, J=
13.3, 7.7 Hz, 1H), 4.00 (ddd, J=7.7, 7.7, 3.6 Hz, 1H), 3.15
(ddd, J=11.8, 5.2, 3.5 Hz, 1H), 2.82 (ddd, J=17.5, 4.4, 4.4 Hz,
1H), 2.72–2.63 (m, 1H), 2.36 (s, 3H), 2.20–2.12 (m, 1H), 2.08–
1.94 (m, 1H); minor diastereomer: δ 8.32 (d, J=8.7 Hz, 2H),
7.25–7.10 (m, 6H), 5.11 (dd, J=13.4, 7.4 Hz, 1H), 4.74 (dd,
J=13.4, 7.4 Hz, 1H), 4.13 (ddd, J=7.6, 7.6, 7.6 Hz, 1H), 3.04
(ddd, J=8.7, 7.6, 4.9 Hz, 1H), 2.91 (ddd, J=18.0, 7.0, 4.7 Hz,
1H), 2.78–2.72 (m, 1H), 2.36 (s, 3H), 2.08–1.94 (m, 1H), 1.77
(dddd, J=14.0, 9.3, 9.3, 4.8 Hz, 1H). 13C{1H} NMR (100 MHz,
CDCl3) major diastereomer: δ 173.4 (C), 171.4 (C), 148.2 (C),
142.8 (C), 138.2 (C), 135.3 (C), 130.9 (2CH), 130.0 (2CH),
129.4 (2CH), 124.4 (2CH), 77.4 (CH2), 46.7 (CH), 45.3 (CH),
32.9 (CH2), 21.4 (CH2), 20.9 (CH3); minor diastereomer:
δ 173.5 (C), 171.5 (C), 148.2 (C), 142.8 (C), 138.1 (C), 135.1
(C), 130.9 (2CH), 130.0 (2CH), 129.2 (2CH), 124.4 (2CH),
78.5 (CH2), 45.5 (CH), 43.6 (CH), 32.6 (CH2), 20.9 (CH2), 20.8
(CH3). HPLC: Chiralpak ID eluted with 1:1 heptane/ethanol at
1 mL/min at 25 °C, UV detection at 260 nm, retention time:
major diastereomer 17.06 min (major enantiomer) and 9.31 min
(minor enantiomer), minor diastereomer 13.02 min (major
enantiomer) and 11.14 min (minor enantiomer).
Compound 4j: Following the general procedure, 3 j (50 mg,
0.12 mmol, dr=15:1, er >200:1) reacted with DPHB (5 mg,
0.026 mmol) for 18 h to provide 4j (38 mg, 76%, dr=2.2:1,
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er=40:1 and 37:1) as a white solid. Rf=0.28 (petrol ether/ethyl
acetate, 3:1). HRMS (ESI+) m/z calcd for C20H20 N3O7+ [M+
H]+ =414.1296, found=414.1300. 1H NMR (400 MHz,
CDCl3) major diastereomer: δ 8.31 (d, J=8.7 Hz, 2H), 7.17 (d,
J=8.7 Hz, 2H), 7.16 (d, J=8.7 Hz, 2H), 6.89 (d, J=8.7 Hz,
2H), 5.18 (dd, J=13.3, 7.5 Hz, 1H), 5.00 (dd, J=13.3, 7.8 Hz,
1H), 3.97 (ddd, J=7.7, 7.7, 3.6 Hz, 1H), 3.82 (s, 3H), 3.14
(ddd, J=11.8, 5.1, 3.6 Hz, 1H), 2.82 (ddd, J=17.4, 4.3, 4.3 Hz,
1H), 2.72 (dddd, J=12.6, 9.0, 5.8, 5.8 Hz, 1H), 2.22–2.08 (m,
1H), 2.07–1.93 (m, 1H); minor diastereomer: δ 8.31 (d, J=
8.7 Hz, 2H), 7.24 (d, J=8.7 Hz, 2H), 7.14 (d, J=8.7 Hz, 2H),
6.91 (d, J=8.7 Hz, 2H), 5.09 (dd, J=13.3, 7.4 Hz, 1H), 4.73
(dd, J=13.3, 7.5 Hz, 1H), 4.13 (ddd, J=7.6, 7.6, 7.6 Hz, 1H),
3.81 (s, 3H), 3.02 (ddd, J=9.0, 9.0, 4.9 Hz, 1H), 2.91 (ddd, J=
17.9, 6.8, 4.8 Hz, 1H), 2.72 (dddd, J=12.6, 9.0, 5.8, 5.8 Hz,
1H), 2.07–1.93 (m, 1H), 1.77 (dddd, J=14.1, 9.5, 9.0, 4.8 Hz,
1H). 13C{1H} NMR (100 MHz, CDCl3) major diastereomer:
δ 172.8 (C), 171.1 (C), 159.9 (C), 147.8 (C), 140.8 (C), 130.0
(2CH), 129.9 (C), 127.7 (2CH), 124.6 (2CH), 114.7 (2CH),
77.7 (CH2), 55.5 (CH3), 45.5 (CH), 45.4 (CH), 32.4 (CH2), 21.7
(CH2); minor diastereomer: δ 172.9 (C), 171.2 (C), 159.8 (C),
147.8 (C), 140.8 (C), 130.0 (2 CH), 129.4 (C), 127.9 (2CH),
124.6 (2CH), 114.9 (2CH), 78.1 (CH2), 55.5 (CH3), 45.1 (CH),
42.9 (CH), 31.2 (CH2), 20.4 (CH2). HPLC: Chiralpak IF eluted
with 1:1 heptane/ethanol at 1 mL/min at 25 °C, UV detection at
260 and 280 nm, retention time: major diastereomer 31.31 min
(major enantiomer) and 16.87 min (minor enantiomer), minor
diastereomer 21.34 min (major enantiomer) and 25.29 min
(minor enantiomer).
Compound 4k: Following the general procedure, 3k (54 mg,
0.12 mmol, dr >20:1, er >200:1) reacted with DPHB (5 mg,
0.026 mmol) for 15 h to provide 4k (37 mg, 69%, dr=1.8:1,
er=75:1 and 6.4:1) as a white solid. Rf=0.30 (petrol ether/
ethyl acetate, 3:1). HRMS (ESI+) m/z calcd for
C19H20BrN4O6+ [M+NH4]+ =479.0561, found=479.0562. 1H
NMR (400 MHz, CDCl3) major diastereomer: δ 8.32 (d, J=
8.7 Hz, 2H), 7.52 (d, J=8.7 Hz, 2H), 7.17 (d, J=8.8 Hz, 2H),
7.15 (d, J=8.8 Hz, 2H), 5.17 (dd, J=13.5, 7.2 Hz, 1H), 5.04
(dd, J=13.4, 8.0 Hz, 1H), 4.01 (ddd, J=7.6, 7.6, 3.6 Hz, 1H),
3.16 (ddd, J=12.6, 4.9, 3.7 Hz, 1H), 2.98–2.84 (m, 1H), 2.82–
2.68 (m, 1H), 2.18–2.11 (m, 1H), 2.08–1.88 (m, 1H); minor
diastereomer: δ 8.32 (d, J=8.7 Hz, 2H), 7.53 (d, J=8.7 Hz,
2H), 7.24 (d, J=8.8 Hz, 2H), 7.13 (d, J=8.8 Hz, 2H), 5.12 (dd,
J=13.4, 7.3 Hz, 1H), 4.75 (dd, J=13.4, 7.6 Hz, 1H), 4.18
(ddd, J=7.5, 7.5,7.5 Hz, 1H), 3.03 (ddd, J=10.0, 7.8, 4.8 Hz,
1H), 2.98–2.84 (m, 1H), 2.73 (dd, J=12.9, 4.9 Hz, 1H), 2.07–
1.90 (m, 1H), 1.76 (dddd, J=14.7, 10.2, 10.2, 4.7 Hz, 1H). 13C
{1H} NMR (100 MHz, d8-tetrahydrofuran) major diastereomer:
δ 173.3 (C), 171.4 (C), 148.3 (C), 142.7 (C), 137.8 (C), 132.5
(2CH), 131.6 (2CH), 130.9 (2CH), 124.4 (2CH), 122.4 (C),
77.0 (CH2), 44.6 (CH), 45.0 (CH), 33.0 (CH2), 21.4 (CH2);
minor diastereomer: δ 173.3 (C), 171.4 (C), 148.3 (C), 142.7
(C), 134.5 (C), 132.5 (2CH), 131.5 (2CH), 130.9 (2CH), 124.4
(2CH), 122.4 (C), 78.0 (CH2), 45.3 (CH), 43.3 (CH), 32.0
(CH2), 20.8 (CH2). HPLC: Chiralpak IC eluted with 7:3
heptane/ethanol at 1 mL/min at 25 °C, UV detection at 280 nm,
retention times: major diastereomer 12.64 min (major enantiom-
er) and 9.45 min (minor enantiomer), minor diastereomer
10.38 min (major enantiomer) and 15.81 min (minor enantiom-
er).
Compound 4 l: Following the general procedure, 3 l (50 mg,
0.12 mmol, dr >20:1, er=39:1) reacted with DPHB (5 mg,
0.026 mmol) for 15 h to provide 4 l (22 mg, 44%, dr >20:1,
er=50:1) as a white solid. Rf=0.36 (petrol ether/ethyl acetate,
1:1). [α]D25= +21.7 (c=0.5, CHCl3). HRMS (ESI+) m/z calcd
for C19H20N5O8+ [M+NH4]+ =446.1306, found=446.1307.
1H NMR (400 MHz, CDCl3): δ 8.33 (d, J=8.8 Hz, 2H), 8.25
(d, J=8.8 Hz, 2H), 7.50 (d, J=8.8 Hz, 2H), 7.19 (d, J=
8.8 Hz, 2H), 5.17 (dd, J=10.8, 3.2 Hz, 1H), 5.14 (dd, J=10.8,
2.8 Hz, 1H), 4.21 (ddd, J=7.4, 3.8, 3.8 Hz, 1H), 3.23 (ddd, J=
8.6, 4.6, 4.6 Hz, 1H), 2.97 (ddd, J=17.7, 4.4, 2.9 Hz, 1H), 2.80
(ddd, J=17.7, 13.5, 5.3 Hz, 1H), 2.18 (dddd, J=13.1, 5.1, 5.1,
2.9 Hz, 1H), 1.94 (dddd, J=13.3, 13.3, 13.3, 4.5 Hz, 1H). 13C
{1H} NMR (100 MHz, d6-acetone): δ 173.7 (C), 172.2 (C),
148.5 (C), 148.4 (C), 146.7 (C), 143.2 (C), 131.4 (2CH), 131.1
(2CH), 124.8 (2CH), 124.6 (2CH), 77.2 (CH2), 46.9 (CH), 44.9
(CH), 33.2 (CH2), 21.1 (CH2). HPLC: Chiralpak IC eluted with
2:2:1 heptane/ethanol/chloroforme at 1 mL/min at 25 °C, UV
detection at 254 nm, retention time: major enantiomer
10.63 min, minor enantiomer 8.03 min.
Compound 4m: Following the general procedure, 3m (60 mg,
0.16 mmol, dr=28:1, er=100:1) reacted with DPHB (6 mg,
0.032 mmol) for 15 h to provide 4m (41 mg, 68%, dr=2.4:1,
er=39:1 and 5.5:1) as a white solid. Rf=0.30 (petrol ether/
ethyl acetate, 3:1). HRMS (ESI+) m/z calcd for C17H19N4O6S+
[M+NH4]+ =407.1020, found=407.1019. 1H NMR
(400 MHz, CDCl3) major diastereomer: δ 8.33 (d, J=8.7 Hz,
2H), 7.33–7.30 (m, 1H), 7.24 (d, J=8.7 Hz, 2H), 7.04–6.94 (m,
2H), 5.23 (dd, J=13.5, 7.3 Hz, 1H), 4.99 (dd, J=13.5, 7.4 Hz,
1H), 4.32 (ddd, J=7.4, 7.4, 3.3 Hz, 1H), 3.20 (ddd, J=12.4,
5.2, 3.3 Hz, 1H), 3.01–2.85 (m, 1H), 2.83–2.73 (m, 1H), 2.22–
2.14 (m, 1H), 2.08–2.00 (m, 1H); minor diastereomer: δ 8.32
(d, J=8.7 Hz, 2H), 7.33–7.30 (m, 1H), 7.22 (d, J=8.7 Hz, 2H),
7.04–6.94 (m, 2H), 5.03 (dd, J=13.1, 8.3 Hz, 1H), 4.83 (dd,
J=10.2, 6.8 Hz, 1H), 4.69 (dd, J=14.6, 6.5 Hz, 1H), 3.08–3.02
(m, 1H), 3.00–2.88 (m, 1H), 2.83–2.73 (m, 1H), 2.13–2.09 (m,
1H), 1.95–1.85 (m, 1H). 13C{1H} NMR (100 MHz, d8-tetrahy-
drofuran) major diastereomer: δ 173.4 (C), 171.4 (C), 148.3
(C), 142.6 (C), 140.0 (C), 130.9 (2CH), 128.2 (CH), 127.4
(CH), 126.3 (CH), 124.4 (2CH), 79.1 (CH2), 45.8 (CH), 41.9
(CH), 33.0 (CH2), 22.2 (CH2); minor diastereomer: δ 173.0 (C),
171.4 (C), 148.3 (C), 142.8 (C), 139.8 (C), 130.9 (2CH), 127.4
(CH), 127.3 (CH), 126.0 (CH), 124.4 (2CH), 78.1 (CH2), 46.0
(CH), 39.3 (CH), 32.3 (CH2), 20.1 (CH2). HPLC: Chiralpak IC
eluted with 3:2 heptane/ethanol at 1 mL/min at 25 °C, UV
detection 254 nm, retention time: major diastereomer 9.82 min
(major enantiomer) and 7.46 min (minor enantiomer), minor
diastereomer 8.88 min (major enantiomer) and 12.51 min
(minor enantiomer).
Compound 4n: Following the general procedure, 3n (70 mg,
0.19 mmol, dr=15:1, er=48:1) reacted with DPHB (7 mg,
0.037 mmol) for 15 h to provide 4n (57 mg, 81%, dr=2:1, er=
28:1 and 46:1) as a white solid. Rf=0.28 (petrol ether/ethyl
acetate, 3:1). HRMS (ESI+) m/z calcd for C17H19N4O7+ [M+
NH4]+ =391.1248, found=391.1248. 1H NMR (400 MHz,
CDCl3) major diastereomer: δ 8.31 (d, J=8.8 Hz, 2H), 7.43 (br
s, 1H), 7.37 (br s, 1H), 7.19 (d, J=8.8 Hz, 2H), 6.30 (br s, 1H),
5.12 (dd, J=13.3, 7.5 Hz, 1H), 4.91 (dd, J=13.3, 7.6 Hz, 1H),
3.89 (ddd, J=7.5, 7.5, 3.0 Hz, 1H), 3.11 (ddd, J=12.2, 5.6,
3.1 Hz, 1H), 3.00–2.90 (m, 1H), 2.85–2.71 (m, 1H), 2.14–1.98
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(m, 2H); minor diastereomer: δ 8.30 (d, J=8.8 Hz, 2H), 7.45
(br s, 1H), 7.35 (br s, 1H), 7.21 (d, J=8.8 Hz, 2H), 6.28 (br s,
1H), 4.89 (dd, J=12.9, 8.4 Hz, 1H), 4.71 (dd, J=12.9, 7.1 Hz,
1H), 4.35 (dd, J=13.5, 7.5 Hz, 1H), 2.99 (dd, J=10.4, 4.8 Hz,
1H), 2.97–2.87 (m, 1H), 2.85–2.71 (m, 1H), 2.14–1.98 (m, 1H),
1.92–1.81 (m, 1H). 13C{1H} NMR (100 MHz, d8-tetrahydrofur-
an) major diastereomer: δ 173.7 (C), 171.4 (C), 148.2 (C),
144.3 (CH), 142.7 (CH), 142.2 (CH), 130.9 (2CH), 124.4
(2CH), 122.0 (CH), 111.1 (CH), 78.3 (CH2), 45.7 (CH), 37.6
(CH), 33.0 (CH2), 22.2 (CH2); minor diastereomer: δ 173.3 (C),
171.4 (C), 148.2 (C), 144.2 (CH), 142.7 (CH), 141.9 (CH),
130.9 (2CH), 124.4 (2CH), 121.6 (CH), 110.7 (CH), 77.4
(CH2), 45.1 (CH), 35.2 (CH), 32.3 (CH2), 19.8 (CH2). HPLC:
Chiralpak IC eluted with 4:1 heptane/ethanol at 1 mL/min at
25 °C, UV detection at 254 nm, retention times: major diaster-
eomer 24.80 min (major enantiomer) and 17.08 min (minor
enantiomer), minor diastereomer 18.98 min (major enantiomer)
and 43.32 min (minor enantiomer).
Compound 4o: Following the general procedure, 3o (89 mg,
0.22 mmol, dr=28:1, er=24:1) reacted with DPHB (8 mg,
0.042 mmol) for 24 h to provide 4o (59 mg, 66%, dr=1.9:1,
er=19:1 and 15:1) as a white solid. Rf=0.43 (petrol ether/ethyl
acetate, 3:1). HRMS (ESI+) m/z calcd for C21H25N4O6+ [M+
NH4]+ =429.1769, found=429.1770. 1H NMR (400 MHz,
CDCl3) major diastereomer: δ 8.30 (d, J=9.0 Hz, 2H), 7.35–
7.14 (m, 7H), 4.76 (dd, J=12.6, 6.8 Hz, 1H), 4.57–4.48 (m,
1H), 3.03–2.61 (m, 6H), 2.17–1.64 (m, 4H); minor diastereom-
er: δ 8.31 (d, J=9.0 Hz, 2H), 7.35–7.14 (m, 7H), 4.62–4.48 (m,
2H), 3.15–3.05 (m, 1H), 3.03–2.61 (m, 5H), 2.17–1.64 (m, 4H).
13C{1H} NMR (100 MHz, d8-tetrahydrofuran) major diaster-
eomer: δ 173.6 (C), 171.6 (C), 148.2 (C), 142.8 (C), 142.2 (C),
130.9 (2CH), 129.0 (2CH), 129.0 (2CH), 126.7 (CH), 124.3
(2CH), 77.9 (CH2), 44.3 (CH), 38.9 (CH), 34.2 (CH2), 33.3
(CH2), 31.7 (CH2), 20.6 (CH2); minor diastereomer: δ 173.5
(C), 171.6 (C), 148.2 (C), 142.9 (C), 142.2 (C), 130.9 (2CH),
128.9 (2CH), 128.8 (2CH), 126.6 (CH), 124.3 (2CH), 77.0
(CH2), 44.7 (CH), 38.2 (CH), 34.2 (CH2), 33.1 (CH2), 32.2
(CH2), 19.2 (CH2). HPLC: Chiralpak IE eluted with 1:1
heptane/ethanol at 1 mL/min at 25 °C, UV detection at 260 nm,
retention times: major diastereomer 9.27 min (major enantiom-
er) and 13.88 min (minor enantiomer), minor diastereomer
11.56 min (major enantiomer) and 19.83 min (minor enantiom-
er).
Computational Work
See the Supporting Information.
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